small molecule

DOJOLVI

TRIHEPTANOIN

Loss of exclusivityNovember 2034latest FDA-listed patent expiry

CompanyUltragenyx Pharmaceutical →View the full company profile on CliffBio

Drug detail

Brand name	DOJOLVI
Active ingredient	TRIHEPTANOIN
Strength	100% w/w
Dosage form	LIQUID
Route	ORAL
Modality	Small molecule
FDA approval	June 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
12551461	November 2034	product
8697748	April 2029	product

Regulatory exclusivity

Code	Expires
ODE-311	June 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.